School of Chinese Medicine
Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Our previous studies showed that atractylenolide II (AT-II) has antimelanoma effects in B16 melanoma cells. In this study, we investigated the involvement of STAT3 signalling in the antimelanoma action of AT-II. Daily administration of AT-II (12.5, 25 mg/kg, i.g.) for 14 days significantly inhibited tumor growth in a B16 xenograft mouse model and inhibited the activation/phosphorylation of STAT3 and Src in the xenografts. In B16 and A375 cells, AT-II (20, 40 μm) treatment for 48 h dose-dependently reduced protein expression levels of phospho-STAT3, phospho-Src, as well as STAT3-regulated Mcl-1 and Bcl-xL. Overexpression of a constitutively active variant of STAT3, STAT3C in A375 cells diminished the antiproliferative and apoptotic effects of AT-II. These data suggest that inhibition of STAT3 signalling contributes to the antimelanoma action of AT-II. Our findings shed new light on the mechanism of action underlying the antimelanoma effects of AT-II and provide further pharmacological basis for developing AT-II as a novel melanoma chemopreventive/chemotherapeutic agent.
Atractylenolide II, Melanoma, Src, STAT3
Source Publication Title
Link to Publisher's Edition
Fu, X., Chou, G., Kwan, H., Tse, A., Zhao, L., Yuen, T., Cao, H., Yu, H., Chao, X., Su, T., Cheng, B., Sun, X., & Yu, Z. (2014). Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Experimental Dermatology, 23 (11), 855-857. https://doi.org/10.1111/exd.12527